Clinical Studies of Molecular Targeted Therapy for Multiple Myeloma
Tsutomu Kobayashi, Junya Kuroda*, Miki Kiyota, Ryuko Nakayama and Masafumi Taniwaki
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan
- *Corresponding Author:
- Junya Kuroda MD, PhD
Division of Hematology and Oncology
Department of Medicine, Kyoto Prefectural University of Medicine
465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566, Japan
Tel: 081 75 251 5740
Fax: 081 75 251 5743
E-mail: [email protected]
Received Date: October 28, 2011; Accepted Date: December 03, 2011; Published Date: December 05, 2011
Citation: Kobayashi T, Kuroda J, Kiyota M, Nakayama R, Taniwaki M (2011) Clinical Studies of Molecular Targeted Therapy for Multiple Myeloma. Translational Medic S2:002. doi:10.4172/2161-1025.S2-002
Copyright: © 2011 Kobayashi T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells which still remains incurable despite conventional and high-dose chemotherapies. With the introduction of new agents, such as bortezomib, thalidomide, and lenalidomide, there has been significant improvement in treatment outcomes for MM during the last decade. Furthermore, several new novel agents those offer further possibilities for MM patients have become available clinical trials. Nevertheless, it is unclear the appropriate usage of these agents to obtain optimal survivals, for example, whether sequencing of drugs or multi-agent combinations offer the superiority. In this review we will describe the various classes of novel agents being used for MM treatment, including proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors, monoclonal antibodies, and other novel agents, with particularly focus on their mechanisms and clinical efficacy.